siRNA treatment: "A sword-in-the-stone" for acute brain injuries

Genes

Volumn 4, Issue 3, 2013, Pages 435-456

  Fukuda, Andrew M ^a   Badaut, Jerome ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain; Ischemia; RNAi; siRNA; Stroke; Subarachnoid hemorrhage; Traumatic brain injury

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; AQUAPORIN 4; BECLIN 1; CLAUDIN 5; FRIZZLED PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; NANOPARTICLE; PROTEINASE ACTIVATED RECEPTOR 1; PUMA PROTEIN; SMALL INTERFERING RNA; VASCULAR ADHESION PROTEIN 1; ALTEPLASE; CALCIUM; CASPASE 3; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 17; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MICRORNA; UNCLASSIFIED DRUG;

BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EXOSOME; HUMAN; MEMBRANE VESICLE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; BLOOD BRAIN BARRIER; CALCIUM CELL LEVEL; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; GENE DELIVERY SYSTEM; GENE THERAPY; INTRACORTICAL DRUG ADMINISTRATION; INTRAHIPPOCAMPAL DRUG ADMINISTRATION; INTRAPARENCHYMAL DRUG ADMINISTRATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; OSMOTIC PUMP; PROTEIN EXPRESSION; PROTEIN SECRETION; REPEATED DRUG DOSE; RNA PROCESSING;

EID: 84884133017     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes4030435     Document Type: Review

References (83)

1. Burnett, J.C.; Rossi, J.J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J.2011, 6, 1130-1146.
2. Burnett, J.C.; Rossi, J.J. RNA-based therapeutics: Current progress and future prospects. Chem. Biol. 2012, 19, 60-71.
3. Brower, V. RNA interference advances to early-stage clinical trials. J. Nat. Cancer Inst. 2010, 102, 1459-1461.
4. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806-811.
5. Carthew, R.W.; Sontheimer, E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136, 642-655.
6. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409, 363-366.
7. Ketting, R.F.; Fischer, S.E.; Bernstein, E.; Sijen, T.; Hannon, G.J.; Plasterk, R.H. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Gene. Dev.2001, 15, 2654-2659.
8. Montgomery, M.K.; Xu, S.; Fire, A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Nat. Acad. Sci. USA 1998, 95, 15502-15507.
9. Tabernero, J.; Shapiro, G.I.; Lorusso, P.M.; Cervantes, A.; Schwartz, G.K.; Weiss, G.J.; Paz-Ares, L.; Cho, D.C.; Infante, J.R.; Alsina, M.; et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3, 406-417.
10. Thanvi, B.R.; Sprigg, N.; Munshi, S.K. Advances in spontaneous intracerebral haemorrhage. Int. J. Clin. Pract. 2012, 66, 556-564.
11. Caner, B.; Hou, J.; Altay, O.; Fuj, M., 2nd.; Zhang, J.H. Transition of research focus from vasospasm to early brain injury after subarachnoid hemorrhage. J. Neurochem. 2012, 123, 12-21.
12. He, Z.; Ostrowski, R.P.; Sun, X.; Ma, Q.; Huang, B.; Zhan, Y.; Zhang, J.H. CHOP silencing reduces acute brain injury in the rat model of subarachnoid hemorrhage. Stroke 2012, 43, 484-490.
13. He, Z.; Ostrowski, R.P.; Sun, X.; Ma, Q.; Tang, J.; Zhang, J.H. Targeting C/EBP homologous protein with siRNA attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. Exp. Neurol. 2012, 238, 218-224.
14. Yan, J.; Li, L.; Khatibi, N.H.; Yang, L.; Wang, K.; Zhang, W.; Martin, R.D.; Han, J.; Zhang, J.; Zhou, C. Blood-brain barrier disruption following subarchnoid hemorrhage may be faciliated through PUMA induction of endothelial cell apoptosis from the endoplasmic reticulum. Exp. Neurol. 2011, 230, 240-247.
15. Ma, Q.; Manaenko, A.; Khatibi, N.H.; Chen, W.; Zhang, J.H.; Tang, J. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J. Cerebr. Blood Flow Metabol. 2011, 31, 881-893.
16. Zhang, J.H.; Badaut, J.; Tang, J.; Obenaus, A.; Hartman, R.; Pearce, W.J. The vascular neural network-A new paradigm in stroke pathophysiology. Nat. Rev. Neurol. 2012, 8, 711-716.
17. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Adams, R.J.; Berry, J.D.; Brown, T.M.; Carnethon, M.R.; Dai, S.; de Simone, G.; Ford, E.S.; et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 2011, 123, e18-e209.
18. Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995, 333, 1581-1587.
19. The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997, 28, 2109-2118.
20. Dirnagl, U.; Simon, R.P.; Hallenbeck, J.M. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003, 26, 248-254.
21. Dirnagl, U.; Iadecola, C.; Moskowitz, M.A. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. 1999, 22, 391-397.
22. Zheng, Y.Q.; Liu, J.X.; Li, X.Z.; Xu, L.; Xu, Y.G. RNA interference-mediated downregulation of Beclin1 attenuates cerebral ischemic injury in rats. Acta Pharmacol. Sin. 2009, 30, 919-927.
23. Al-Jamal, K.T.; Gherardini, L.; Bardi, G.; Nunes, A.; Guo, C.; Bussy, C.; Herrero, M.A.; Bianco, A.; Prato, M.; Kostarelos, K.; et al. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc. Nat. Acad. Sci. USA 2011, 108, 10952-10957.
24. Kim, H.W.; Cho, K.J.; Lee, S.K.; Kim, G.W. Apoptosis signal-regulating kinase 1 (Ask1) targeted small interfering RNA on ischemic neuronal cell death. Brain Res. 2011, 1412, 73-78.
25. Zhang, J.; Wang, Y.; Zhu, P.; Wang, X.; Lv, M.; Feng, H. siRNA-mediated silence of protease-activated receptor-1 minimizes ischemic injury of cerebral cortex through HSP70 and MAP2. J. Neurol. Sci. 2012, 320, 6-11.
26. Price, M.; Badaut, J.; Thevenet, J.; Hirt, L. Activation of c-Jun in the nuclei of neurons of the CA-1 in thrombin preconditioning occurs via PAR-1. J. Neurosci. Res. 2010, 88, 1338-1347.
27. Thevenet, J.; Angelillo-Scherrer, A.; Price, M.; Hirt, L. Coagulation factor Xa activates thrombin in ischemic neural tissue. J. Neurochem. 2009, 111, 828-836.
28. Chen, C.; Hu, Q.; Yan, J.; Yang, X.; Shi, X.; Lei, J.; Chen, L.; Huang, H.; Han, J.; Zhang, J.H.; et al. Early inhibition of HIF-1alpha with small interfering RNA reduces ischemic-reperfused brain injury in rats. Neurobiol. Dis. 2009, 33, 509-517.
29. Zhao, B.; Zhao, C.Z.; Zhang, X.Y.; Huang, X.Q.; Shi, W.Z.; Fang, S.H.; Lu, Y.B.; Zhang, W.P.; Xia, Q.; Wei, E.Q. The new P2Y-like receptor G protein-coupled receptor 17 mediates acute neuronal injury and late microgliosis after focal cerebral ischemia in rats. Neuroscience 2012, 202, 42-57.
30. Ciana, P.; Fumagalli, M.; Trincavelli, M.L.; Verderio, C.; Rosa, P.; Lecca, D.; Ferrario, S.; Parravicini, C.; Capra, V.; Gelosa, P.; et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006, 25, 4615-4627.
31. Lecca, D.; Trincavelli, M.L.; Gelosa, P.; Sironi, L.; Ciana, P.; Fumagalli, M.; Villa, G.; Verderio, C.; Grumelli, C.; Guerrini, U.; et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One 2008, 3, e3579.
32. Fukuda, A.M.; Badaut, J. Aquaporin 4: A player in cerebral edema and neuroinflammation. J. Neuroinflammation 2012, 9, 279.
33. Loane, D.J.; Byrnes, K.R. Role of microglia in neurotrauma. Neurotherapeutics 2010, 7, 366-377.
34. Bianchi, M.E.; Manfredi, A.A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 2007, 220, 35-46.
35. Kim, I.D.; Lim, C.M.; Kim, J.B.; Nam, H.Y.; Nam, K.; Kim, S.W.; Park, J.S.; Lee, J.K. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J. Control. Release 2010, 142, 422-430.
36. Kim, J.B.; Sig Choi, J.; Yu, Y.M.; Nam, K.; Piao, C.S.; Kim, S.W.; Lee, M.H.; Han, P.L.; Park, J.S.; Lee, J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J. Neurosci. 2006, 26, 6413-6421.
37. Kim, I.D.; Shin, J.H.; Kim, S.W.; Choi, S.; Ahn, J.; Han, P.L.; Park, J.S.; Lee, J.K. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol. Ther. 2012, 20, 829-839.
38. Thorne, R.G.; Emory, C.R.; Ala, T.A.; Frey, W.H., 2nd. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995, 692, 278-282.
39. Thorne, R.G.; Hanson, L.R.; Ross, T.M.; Tung, D.; Frey, W.H., 2nd. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008, 152, 785-797.
40. Thorne, R.G.; Pronk, G.J.; Padmanabhan, V.; Frey, W.H., 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127, 481-496.
41. Liu, X.F.; Fawcett, J.R.; Thorne, R.G.; DeFor, T.A.; Frey, W.H., 2nd. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J. Neurol. Sci. 2001, 187, 91-97.
42. Faul, M.; Xu, L.; Wald, M.M.; Coronado, V. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths, 2002-2006; CDC, National Center for Injury Prevention and Control: Atlanta, GA, USA, 2010.
43. Pop, V.; Badaut, J. A neurovascular perspective for long-term changes after brain trauma. Transl. Stroke Res. 2011, 2, 533-545.
44. Morales, D.M.; Marklund, N.; Lebold, D.; Thompson, H.J.; Pitkanen, A.; Maxwell, W.L.; Longhi, L.; Laurer, H.; Maegele, M.; Neugebauer, E.; et al. Experimental models of traumatic brain injury: Do we really need to build a better mousetrap? Neuroscience 2005, 136, 971-989.
45. Miyashita, R.; Chen, L.; Oshiro, H.; Uchino, H.; Shibasaki, F. Int6 silencing causes induction of angiogenic factors in neuronal cells via accumulation of hypoxia-inducible factor 2alpha and decreases brain damage in rats. Neurosci. Lett. 2012, 528, 83-88.
46. Woodcock, T.; Morganti-Kossmann, M.C. The role of markers of inflammation in traumatic brain injury. Front. Neurol. 2013, 4, 18.
47. Campbell, M.; Hanrahan, F.; Gobbo, O.L.; Kelly, M.E.; Kiang, A.S.; Humphries, M.M.; Nguyen, A.T.; Ozaki, E.; Keaney, J.; Blau, C.W.; et al. Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury. Nat. Commun. 2012, 3, 849.
48. Badaut, J.; Ashwal, S.; Obenaus, A. Aquaporins in cerebrovascular disease: A target for treatment of brain edema? Cerebrovasc. Dis. 2011, 31, 521-531.
49. Fukuda, A.M.; Pop, V.; Spagnoli, D.; Ashwal, S.; Obenaus, A.; Badaut, J. Delayed increase of astrocytic aquaporin 4 after juvenile traumatic brain injury: Possible role in edema resolution? Neuroscience 2012, 222, 366-378.
50. Fukuda, A.M.; Adami, A.; Pop, V.; Bellone, J.A.; Coats, J.S.; Hartman, R.E.; Ashwal, S.; Obenaus, A.; Badaut, J. Posttraumatic reduction of edema with aquaporin-4 RNA interference improves acute and chronic functional recovery. J. Cerebr. Blood Flow Metabol. 2013, doi:10.1038/jcbfm.2013.118.
51. Niu, L.J.; Xu, R.X.; Zhang, P.; Du, M.X.; Jiang, X.D. Suppression of Frizzled-2-mediated Wnt/Ca(2)(+) signaling significantly attenuates intracellular calcium accumulation in vitro and in a rat model of traumatic brain injury. Neuroscience 2012, 213, 19-28.
52. Schanne, F.A.; Kane, A.B.; Young, E.E.; Farber, J.L. Calcium dependence of toxic cell death: A final common pathway. Science 1979, 206, 700-702.
53. Mathupala, S.P. Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin. Ther. Patents 2009, 19, 137-140.
54. Zhou, J.; Shum, K.T.; Burnett, J.C.; Rossi, J.J. Nanoparticle-based delivery of RNAi therapeutics: Progress and challenges. Pharmaceuticals 2013, 6, 85-107.
55. Shim, M.S.; Kwon, Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010, 277, 4814-4827.
56. Van de Water, F.M.; Boerman, O.C.; Wouterse, A.C.; Peters, J.G.; Russel, F.G.; Masereeuw, R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 2006, 34, 1393-1397.
57. Walton, S.P.; Wu, M.; Gredell, J.A.; Chan, C. Designing highly active siRNAs for therapeutic applications. FEBS J. 2010, 277, 4806-4813.
58. Danielyan, L.; Schafer, R.; von Ameln-Mayerhofer, A.; Buadze, M.; Geisler, J.; Klopfer, T.; Burkhardt, U.; Proksch, B.; Verleysdonk, S.; Ayturan, M.; et al. Intranasal delivery of cells to the brain. Eur. J. Cell Biol. 2009, 88, 315-324.
59. Danielyan, L.; Klein, R.; Hanson, L.R.; Buadze, M.; Schwab, M.; Gleiter, C.H.; Frey, W.H. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuv. Res. 2010, 13, 195-201.
60. Gomez, D.; Martinez, J.A.; Hanson, L.R.; Frey, W.H., 2nd.; Toth, C.C. Intranasal treatment of neurodegenerative diseases and stroke. Front. Biosci. 2012, 4, 74-89.
61. Hanson, L.R.; Frey, W.H., 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008, 9, S5.
62. Hanson, L.R.; Roeytenberg, A.; Martinez, P.M.; Coppes, V.G.; Sweet, D.C.; Rao, R.J.; Marti, D.L.; Hoekman, J.D.; Matthews, R.B.; Frey, W.H., 2nd.; et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 2009, 330, 679-686.
63. Liu, X.F.; Fawcett, J.R.; Thorne, R.G.; Frey, W.H., 2nd. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci. Lett. 2001, 308, 91-94.
64. Wei, G.; Wang, D.; Lu, H.; Parmentier, S.; Wang, Q.; Panter, S.S.; Frey, W.H., 2nd.; Ying, W. Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. Front. Biosci. 2007, 12, 4986-4996.
65. Renner, D.B.; Frey, W.H., 2nd.; Hanson, L.R. Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. Neurosci. Lett. 2012, 513, 193-197.
66. Bortolozzi, A.; Castane, A.; Semakova, J.; Santana, N.; Alvarado, G.; Cortes, R.; Ferres-Coy, A.; Fernandez, G.; Carmona, M.C.; Toth, M.; et al. Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol. Psychiatr. 2012, 17, 612-623.
67. Lu, X.X.; McCoy, K.S.; Xu, J.L.; Hu, W.K.; Chen, H.B. Small interfering RNA targeting T-cell Ig mucin-3 decreases allergic airway inflammation and hyperresponsiveness. Inflammation 2013, 36, 582-591.
68. Massaro, D.; Massaro, G.D.; Clerch, L.B. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287, L1066-L1070.
69. Thorne, R.G.; Frey, W.H., 2nd. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin. Pharmacokinet. 2001, 40, 907-946.
70. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341-345.
71. El Andaloussi, S.; Lakhal, S.; Mager, I.; Wood, M.J. Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev. 2013, 65, 391-397.
72. Wahlgren, J.; Karlson, T.D.L.; Brisslert, M.; Vaziri Sani, F.; Telemo, E.; Sunnerhagen, P.; Valadi, H. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucl. Acids Res. 2012, 40, e130.
73. Cossetti, C.; Smith, J.A.; Iraci, N.; Leonardi, T.; Alfaro-Cervello, C.; Pluchino, S. Extracellular membrane vesicles and immune regulation in the brain. Front. Physiol. 2012, 3, 117.
74. Lai, C.P.; Breakefield, X.O. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front. Physiol. 2012, 3, 228.
75. Badaut, J.; Ashwal, S.; Adami, A.; Tone, B.; Recker, R.; Spagnoli, D.; Ternon, B.; Obenaus, A. Brain water mobility decreases after astrocytic aquaporin-4 inhibition using RNA interference. J. Cerebr. Blood Flow Metabol. 2011, 31, 819-831.
76. Davis, M.E.; Chen, Z.G.; Shin, D.M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7, 771-782.
77. Petros, R.A.; DeSimone, J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9, 615-627.
78. Mishima, T.; Mizuguchi, Y.; Kawahigashi, Y.; Takizawa, T.; Takizawa, T. RT-PCR-based analysis of microRNA (miR-1 and-124) expression in mouse CNS. Brain Res. 2007, 1131, 37-43.
79. Saugstad, J.A. MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J. Cerebr. Blood Flow Metabol. 2010, 30, 1564-1576.
80. Linsen, S.E.; de Wit, E.; de Bruijn, E.; Cuppen, E. Small RNA expression and strain specificity in the rat. BMC Genomics 2010, 11, 249.
81. Hu, Z.; Yu, D.; Almeida-Suhett, C.; Tu, K.; Marini, A.M.; Eiden, L.; Braga, M.F.; Zhu, J.; Li, Z. Expression of miRNAs and their cooperative regulation of the pathophysiology in traumatic brain injury. PLoS One 2012, 7, e39357.
82. Liu, N.K.; Xu, X.M. MicroRNA in central nervous system trauma and degenerative disorders. Physiol. Genomics 2011, 43, 571-580.
83. Ziu, M.; Fletcher, L.; Rana, S.; Jimenez, D.F.; Digicaylioglu, M. Temporal differences in microRNA expression patterns in astrocytes and neurons after ischemic injury. PLoS One 2011, 6, e14724.